DOI: 10.12890/2021_002652
Cutaneous and Ganglion Sarcoidosis Induced by Polycaprolactone Facial Filler: A New Expression of ASIA Syndrome?
Authors
juan.ortiz.alvarez94@gmail.com
Keywords
Polycaprolactone filler, sarcoidosis, ASIA syndromeAbstract
Dermal fillers are applied using a minimally invasive technique with a good safety profile. However, they can have side effects. We present the case of a patient who, 2 months after undergoing polycaprolactone (Ellansé®) injections, developed nodular facial and nodal lesions that were compatible with sarcoidosis on histology. This complication has not been previously described for polycaprolactone and could be the expression of an autoimmune syndrome induced by adjuvants.
References
- SWanat KA, Rosenbach M. Cutaneous sarcoidosis. Clin Chest Med 2015;36(4):685–702. Available from: http://dx.doi.org/10.1016/j.ccm.2015.08.010
- Levy L, Emer J. Complications of minimally invasive cosmetic procedures: prevention and management. J Cutan Aesthet Surg 2012;5(2):121–132.
- Lin SL, Christen MO. Polycaprolactone-based dermal filler complications: a retrospective study of 1111 treatments. J Cosmet Dermatol 2020;19(8):1907–1914.
- Sommerfeld S, Cherry C, Schwab R, Chung L, Maestas DJ, Laffont P, et al. Interleukin-36?–producing macrophages drive IL-17–mediated fibrosis. Sci Immunol 2019;11(4):eaax4783.
- Alijotas-Reig J. Human adjuvant-related syndrome or autoimmune/inflammatory syndrome induced by adjuvants. Where have we come from? Where are we going? A proposal for new diagnostic criteria.Lupus 2015;24(10):1012–1018.